Pharmacogenetics in inflammatory bowel disease

doi:10.3748/wjg.v12.i23.3657

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 23

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4533)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

363

HTML

3799

Figures (1-3)

204

Tables (1-2)

167

Sum=4533

Jun 21, 2006 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (35)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 21, 2006; 12(23): 3657-3667
Published online Jun 21, 2006. doi: 10.3748/wjg.v12.i23.3657

Table 1 Interpretation by PCR based methods of TPMT activity

Genotype		PCR	Risk of hematopoietictoxicity
238G/238G	1/1	238 GG	-7%
460G/460G		460 GG
719A/719A		719 AA
238G/238G	1/3A	238GG	-35%
460A/460A		460GA
719A/719G		719AG
238G/238G	1/3B	238GG	-35%
460G/460A		460GA
719A/719A		719AA
238G/238G	1/3C	238GG	-35%
460G/460G		460GG
719A/719G		719AG
238G/238G	3B/3C	238GG	-100%
460G/460G		460GG
719A/719G		719AG
238G/238G	3A/3C	238GG	-100%
460A/460G		460GA
719G/719G		719GG
238G/238G	3A/3B	238GG	-100%
460A/460A		460AA
719G/719A		719AG

Patients with *1/3A and *3A/*3C genotype have the same PCR results, however the risk to develop hematopoietic toxicity for patients with 2 low activity alleles is almost 100% compared to 35% only for heterozygous patients.

Table 2 NAT2 phenotypes and genotypes

Mutations	Allele designation	Phenotype
None	NAT2*4 (wild-type)	normal
T341C, C481T, A803G	NAT2*5B (r3,S1a)	Slow
C282T, G590A	NAT2*6A (M2)	Slow
T341C, C481T	NAT2*5A (M1)	Slow
T341C, CA803G	NAT2*5C (S1c)	Slow
C282T, G857A	NAT2*7B (M3)	Slow
C282T	NAT2*13 (S4)
G590A	NAT2*6B (R2)	Unknown
G191A	NAT2*14A (M4)	Slow
A803G	NAT2*12A	Rapid

Citation: Pierik M, Rutgeerts P, Vlietinck R, Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol 2006; 12(23): 3657-3667
URL: https://www.wjgnet.com/1007-9327/full/v12/i23/3657.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i23.3657